News Vertex bags FDA okay for its non-opioid pain drug Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.
News Vertex weakens after neuropathic pain trial reads out A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data.
News Vertex eyes FDA decision on non-opioid pain drug in January Vertex Pharma has filed for FDA approval of its non-opioid pain drug suzetrigine, starting the clock ticking on a review that should be completed early next year.
R&D Non-opioid painkillers: Another tool to fight the opioid epi... The opioid epidemic is still an ongoing problem and there is no single solution to bring it under control.
News ACIP backs block on flu vaccines with thimerosal additive The new CDC vaccines committee has voted against the use of thimerosal, a preservative that anti-vaccine activists have linked to autism.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
